S&P 500   4,074.11 (+1.65%)
DOW   32,572.46 (+1.08%)
QQQ   303.55 (+1.71%)
AAPL   148.09 (+1.75%)
MSFT   265.05 (+1.36%)
FB   201.44 (+0.70%)
GOOGL   2,317.02 (+1.23%)
AMZN   2,249.19 (+1.49%)
TSLA   752.06 (+3.82%)
NVDA   179.39 (+3.91%)
BABA   90.11 (+4.20%)
NIO   16.34 (+12.30%)
AMD   102.13 (+8.37%)
CGC   5.90 (+2.97%)
MU   73.56 (+4.38%)
T   20.51 (+1.13%)
GE   76.66 (+2.72%)
F   13.39 (+2.61%)
DIS   107.51 (+2.22%)
AMC   12.30 (+5.04%)
PFE   51.47 (+1.58%)
PYPL   78.44 (+1.02%)
NFLX   189.17 (+1.43%)
S&P 500   4,074.11 (+1.65%)
DOW   32,572.46 (+1.08%)
QQQ   303.55 (+1.71%)
AAPL   148.09 (+1.75%)
MSFT   265.05 (+1.36%)
FB   201.44 (+0.70%)
GOOGL   2,317.02 (+1.23%)
AMZN   2,249.19 (+1.49%)
TSLA   752.06 (+3.82%)
NVDA   179.39 (+3.91%)
BABA   90.11 (+4.20%)
NIO   16.34 (+12.30%)
AMD   102.13 (+8.37%)
CGC   5.90 (+2.97%)
MU   73.56 (+4.38%)
T   20.51 (+1.13%)
GE   76.66 (+2.72%)
F   13.39 (+2.61%)
DIS   107.51 (+2.22%)
AMC   12.30 (+5.04%)
PFE   51.47 (+1.58%)
PYPL   78.44 (+1.02%)
NFLX   189.17 (+1.43%)
S&P 500   4,074.11 (+1.65%)
DOW   32,572.46 (+1.08%)
QQQ   303.55 (+1.71%)
AAPL   148.09 (+1.75%)
MSFT   265.05 (+1.36%)
FB   201.44 (+0.70%)
GOOGL   2,317.02 (+1.23%)
AMZN   2,249.19 (+1.49%)
TSLA   752.06 (+3.82%)
NVDA   179.39 (+3.91%)
BABA   90.11 (+4.20%)
NIO   16.34 (+12.30%)
AMD   102.13 (+8.37%)
CGC   5.90 (+2.97%)
MU   73.56 (+4.38%)
T   20.51 (+1.13%)
GE   76.66 (+2.72%)
F   13.39 (+2.61%)
DIS   107.51 (+2.22%)
AMC   12.30 (+5.04%)
PFE   51.47 (+1.58%)
PYPL   78.44 (+1.02%)
NFLX   189.17 (+1.43%)
S&P 500   4,074.11 (+1.65%)
DOW   32,572.46 (+1.08%)
QQQ   303.55 (+1.71%)
AAPL   148.09 (+1.75%)
MSFT   265.05 (+1.36%)
FB   201.44 (+0.70%)
GOOGL   2,317.02 (+1.23%)
AMZN   2,249.19 (+1.49%)
TSLA   752.06 (+3.82%)
NVDA   179.39 (+3.91%)
BABA   90.11 (+4.20%)
NIO   16.34 (+12.30%)
AMD   102.13 (+8.37%)
CGC   5.90 (+2.97%)
MU   73.56 (+4.38%)
T   20.51 (+1.13%)
GE   76.66 (+2.72%)
F   13.39 (+2.61%)
DIS   107.51 (+2.22%)
AMC   12.30 (+5.04%)
PFE   51.47 (+1.58%)
PYPL   78.44 (+1.02%)
NFLX   189.17 (+1.43%)
NASDAQ:MBII

Marrone Bio Innovations (MBII) Stock Forecast, Price & News

$1.06
+0.03 (+2.91%)
(As of 05/17/2022 12:53 PM ET)
Add
Compare
Today's Range
$1.04
$1.09
50-Day Range
$0.70
$1.16
52-Week Range
$0.55
$1.95
Volume
5,008 shs
Average Volume
814,800 shs
Market Capitalization
$193.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.36
30 days | 90 days | 365 days | Advanced Chart
Receive MBII News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.

Marrone Bio Innovations logo

About Marrone Bio Innovations

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

Headlines

Mid-Afternoon Market Update: Nasdaq Down 3%; Accolade Shares Slide
Preview: Marrone Bio Innovations's Earnings
See More Headlines

Industry, Sector and Symbol

Industry
Agricultural chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MBII
Fax
N/A
Employees
153
Year Founded
N/A

Sales & Book Value

Annual Sales
$44.31 million
Book Value
$0.17 per share

Profitability

Net Income
$-16.55 million
Pretax Margin
-37.26%

Debt

Price-To-Earnings

Miscellaneous

Free Float
173,161,000
Market Cap
$193.21 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/11/2022
Today
5/17/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.13 out of 5 stars

Basic Materials Sector

110th out of 246 stocks

Agricultural Chemicals Industry

5th out of 13 stocks

Analyst Opinion: 3.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions

Is Marrone Bio Innovations a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Marrone Bio Innovations stock.
View analyst ratings for Marrone Bio Innovations
or view top-rated stocks.

Are investors shorting Marrone Bio Innovations?

Marrone Bio Innovations saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,360,000 shares, an increase of 31.1% from the April 15th total of 1,800,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 2.5% of the shares of the stock are sold short.
View Marrone Bio Innovations' Short Interest
.

When is Marrone Bio Innovations' next earnings date?

Marrone Bio Innovations is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Marrone Bio Innovations
.

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations, Inc. (NASDAQ:MBII) announced its quarterly earnings data on Wednesday, May, 11th. The basic materials company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.02. Marrone Bio Innovations had a negative net margin of 47.07% and a negative trailing twelve-month return on equity of 65.95%. During the same quarter in the previous year, the firm posted ($0.02) earnings per share.
View Marrone Bio Innovations' earnings history
.

What price target have analysts set for MBII?

4 equities research analysts have issued 1 year price objectives for Marrone Bio Innovations' shares. Their forecasts range from $1.30 to $2.50. On average, they expect Marrone Bio Innovations' share price to reach $2.08 in the next twelve months. This suggests a possible upside of 95.8% from the stock's current price.
View analysts' price targets for Marrone Bio Innovations
or view top-rated stocks among Wall Street analysts.

Who are Marrone Bio Innovations' key executives?
Marrone Bio Innovations' management team includes the following people:
  • Mr. Kevin R. Helash, CEO & Director (Age 57, Pay $418.62k)
  • Dr. Pamela G. Marrone Ph.D., Founder, Advisor & Non-Employee Director (Age 65, Pay $408.63k)
  • Mr. LaDon Johnson CPA, CPA, Interim Chief Financial Officer
  • Dr. Amit Vasavada Ph.D., Sr. VP of Research Devel. & Chief Technical Officer (Age 67)
  • Ms. Linda V. Moore, Chief Compliance Officer, Chief Legal Officer & Sec. (Age 75)
  • Andre Trepanier, Director of Marketing
  • Mr. Barner Jones, Director of National Sales & Account Management
  • Mr. Matti Tiainen, Sr. VP of International Sales (Age 33)
  • Mr. Keith J. Pitts, Sr. VP of Regulatory & Gov. Affairs and Chief Sustainability Officer (Age 58)
What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Ekso Bionics (EKSO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Enerplus (ERF), ADMA Biologics (ADMA), Great Panther Mining (GPL), OrganiGram (OGI), (XXII) and Aeterna Zentaris (AEZS).

What is Marrone Bio Innovations' stock symbol?

Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."

Who are Marrone Bio Innovations' major shareholders?

Marrone Bio Innovations' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.68%), Vanguard Group Inc. (2.49%), Shay Capital LLC (1.37%), Primecap Management Co. CA (0.83%), State Street Corp (0.78%) and Ergoteles LLC (0.50%). Company insiders that own Marrone Bio Innovations stock include Pamela G Marrone and Pamela G Marrone.
View institutional ownership trends for Marrone Bio Innovations
.

Which institutional investors are selling Marrone Bio Innovations stock?

MBII stock was sold by a variety of institutional investors in the last quarter, including Shay Capital LLC, Vanguard Group Inc., JPMorgan Chase & Co., FNY Investment Advisers LLC, BlackRock Inc., Primecap Management Co. CA, Northern Trust Corp, and Oak Family Advisors LLC.
View insider buying and selling activity for Marrone Bio Innovations
or view top insider-selling stocks.

Which institutional investors are buying Marrone Bio Innovations stock?

MBII stock was acquired by a variety of institutional investors in the last quarter, including Ergoteles LLC, Gardner Lewis Asset Management L P, EHP Funds Inc., Vident Investment Advisory LLC, State Street Corp, Charles Schwab Investment Management Inc., Clear Harbor Asset Management LLC, and Allspring Global Investments Holdings LLC.
View insider buying and selling activity for Marrone Bio Innovations
or or view top insider-buying stocks.

How do I buy shares of Marrone Bio Innovations?

Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marrone Bio Innovations' stock price today?

One share of MBII stock can currently be purchased for approximately $1.06.

How much money does Marrone Bio Innovations make?

Marrone Bio Innovations has a market capitalization of $193.21 million and generates $44.31 million in revenue each year. The basic materials company earns $-16.55 million in net income (profit) each year or ($0.120010) on an earnings per share basis.

How many employees does Marrone Bio Innovations have?

Marrone Bio Innovations employs 153 workers across the globe.

What is Marrone Bio Innovations' official website?

The official website for Marrone Bio Innovations is www.marronebioinnovations.com.

How can I contact Marrone Bio Innovations?

Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at (530) 750-2800 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.